Skip to main content
Top

Breast Cancer Research and Treatment

Issue 1/2008

Content (20 Articles)

Review

Current management of DCIS: a review

Neill Patani, Bruno Cutuli, Kefah Mokbel

Preclinical Study

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

David S. P. Tan, Caterina Marchió, Robin L. Jones, Kay Savage, Ian E. Smith, Mitch Dowsett, Jorge S. Reis-Filho

Preclinical Study

Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer

Orla Mc Cormack, Wen Y. Chung, Patricia Fitzpatrick, Fiachra Cooke, Barbara Flynn, Michele Harrison, Edward Fox, Emma Gallagher, Aloysius McGoldrick, Peter A. Dervan, Amanda McCann, Michael J. Kerin

Preclinical Study

Identification of the functional role of AF1Q in the progression of breast cancer

Xin-Zhong Chang, Da-Qiang Li, Yi-Feng Hou, Jiong Wu, Jin-Song Lu, Gen-Hong Di, Wei Jin, Zhou-Luo Ou, Zhen-Zhou Shen, Zhi-Ming Shao

Preclinical Study

MAZ drives tumor-specific expression of PPAR gamma 1 in breast cancer cells

Xin Wang, R. Chase Southard, Clinton D. Allred, Dominique R. Talbert, Melinda E. Wilson, Michael W. Kilgore

Preclinical Study

Estrogen receptor α, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers

Minjie Wei, Jinhua Xu, James Dignam, Rita Nanda, Lise Sveen, James Fackenthal, Tatyana A. Grushko, Olufunmilayo I. Olopade

Preclinical Study

Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast

Emad A. Rakha, Maysa E. El-Sayed, Sindhu Menon, Andrew R. Green, Andrew H. S. Lee, Ian O. Ellis

Preclinical Study

Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer

Paul A. Foster, Surinder K. Chander, Michael F. C. Parsons, Simon P. Newman, L. W. Lawrence Woo, Barry V. L. Potter, Michael J. Reed, Atul Purohit

Epidemiology

The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study

Bernd Frank, Sushila H. Rigas, Justo Lorenzo Bermejo, Miriam Wiestler, Kerstin Wagner, Kari Hemminki, Malcolm W. Reed, Christian Sutter, Barbara Wappenschmidt, Sabapathy P. Balasubramanian, Alfons Meindl, Marion Kiechle, Peter Bugert, Rita K. Schmutzler, Claus R. Bartram, Christina Justenhoven, Yon-Dschun Ko, Thomas Brüning, Hiltrud Brauch, Ute Hamann, Paul P. D. Pharoah, Alison M. Dunning, Karen A. Pooley, Douglas F. Easton, Angela Cox, Barbara Burwinkel

Epidemiology

Polymorphism of cytosolic serine hydroxymethyltransferase, estrogen and breast cancer risk among Chinese women in Taiwan

Chun-Wen Cheng, Jyh-Cherng Yu, Chiun-Sheng Huang, Jia-Ching Shieh, Yi-Ping Fu, Hsiao-Wei Wang, Pei-Ei Wu, Chen-Yang Shen

Epidemiology

Association of polymorphisms of angiogenesis genes with breast cancer

Bryan P. Schneider, Milan Radovich, George W. Sledge, Jason D. Robarge, Lang Li, Anna M. Storniolo, Suzanne Lemler, Anne T. Nguyen, Bradley A. Hancock, Michael Stout, Todd Skaar, David A. Flockhart

Epidemiology

Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer

Kari Hemminki, Hui Zhang, Jan Sundquist, Justo Lorenzo Bermejo

Epidemiology

The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer

Christina Justenhoven, Christiane B. Pierl, Susanne Haas, Hans-Peter Fischer, Christian Baisch, Ute Hamann, Volker Harth, Beate Pesch, Thomas Brüning, Caren Vollmert, Thomas Illig, Jürgen Dippon, Yon-Dschun Ko, Hiltrud Brauch

Clinical Trial

Influence of preoperative MRI on the surgical management of patients with operable breast cancer

Michael Braun, Martin Pölcher, Simone Schrading, Oliver Zivanovic, Theresa Kowalski, Uta Flucke, Claudia Leutner, Tong-Wong Park-Simon, Christian Rudlowski, Walther Kuhn, Christiane K. Kuhl

Letter to the Editor

Medical cost-offsets from psychosocial care in breast cancer

Louisa Gordon, Monika Janda

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine